Inactive Instrument

First Light Acquisition Group, Inc. Nyse

Equities

FLAG.U

US3207032000

First Light Acquisition Group, Inc. announced that it has received $5.095733 million in funding from First Light Acquisition Group, LLC, and another investor

September 13, 2021

On September 14, 2021, First Light Acquisition Group, Inc closed the transaction. The company issued 3,397,155 warrants for the gross proceeds of $5,095,733. First Light Acquisition Group, LLC subscribed for 2,583,333 warrants and Metric Finance Holdings I, LLC subscribed for 813,822 warrants.

Latest news about First Light Acquisition Group, Inc.

Calidi Biotherapeutics Prices $6.1 Million Offering	Apr. 16	MT
H.C. Wainwright Lowers Price Target on Calidi Biotherapeutics to $2 From $11, Maintains Buy Rating	Mar. 21	MT
Calidi Biotherapeutics, Inc. announced that it has received $3.5 million in funding	Mar. 20	CI
Calidi Biotherapeutics, Inc. announced that it expects to receive $3.5 million in funding	Mar. 07	CI
Sector Update: Health Care Stocks Firmer Late Afternoon	Feb. 07	MT
Calidi Biotherapeutics to Sell Common Stock	Feb. 07	MT
Calidi Biotherapeutics, Inc. announced that it has received $1 million in funding	Jan. 25	CI
Calidi Biotherapeutics, Inc. Announces Scientific and Medical Advisory Board Appointments	Jan. 08	CI
Calidi Biotherapeutics, Inc.(NYSEAM:CLDI) added to S&P TMI Index	Dec. 18	CI
Calidi Biotherapeutics Announces Directorate Changes	Dec. 12	CI
Calidi Biotherapeutics, Inc. announced that it expects to receive $25 million in funding from Yorkville Advisors Global LP	Dec. 09	CI
Calidi Biotherapeutics, Inc. Announces the Resignation of Alfonso Zulueta as A Director, Including His Position on Audit Committee of the Board	Dec. 05	CI
HC Wainwright Starts Calidi Biotherapeutics With Buy Rating, $11 Price Target	Nov. 22	MT
Calidi Biotherapeutics Gets US Patent for Cancer Treatment Technology Platform	Nov. 20	MT
Calidi Biotherapeutics, Inc. Presents Data on CLD-201 Demonstrating Inhibition of Tumor Growth and Induction of Robust Anti-Tumor Immunity at the Society for Immunotherapy of Cancer's 38th Annual Meeting	Nov. 03	CI
Calidi Biotherapeutics, Inc. Announces Key Leadership Promotions and New Board Appointment	Nov. 01	CI
Calidi Biotherapeutics, Inc. announced a financing transaction	Oct. 31	CI
Calidi Biotherapeutics Names Andrew Jackson as Chief Financial Officer	23-10-30	MT
Calidi Biotherapeutics, Inc. Enters into an Employment Agreement with Andrew Jackson to Serve as Chief Financial Officer	23-10-30	CI
Calidi Biotherapeutics, Inc. Announces Resignation of Tony Kalajian as Interim Chief Financial Officer	23-10-27	CI
Calidi Biotherapeutics, Inc. Announces Resignation of Tony Kalajian as Chief Accounting Officer	23-10-27	CI
Calidi Biotherapeutics, Inc. Appoints Alan R. Stewart as the Class I Director	23-10-24	CI
Calidi Biotherapeutics, Inc. Announces the Resignation of Dr. Heehyoung Lee, Including All Her Positions on the Committees of the Board	23-10-16	CI
Baird Starts Calidi Biotherapeutics With Outperform Rating, Price Target is $9	23-10-09	MT
Calidi Biotherapeutics Announces Primary, Secondary Offering of Shares, Warrants	23-10-06	MT

Chart First Light Acquisition Group, Inc.

Duration

Period

Chart First Light Acquisition Group, Inc.

More charts

Company Profile

First Light Acquisition Group, Inc is a blank check company. The Company is formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The Company intends to focus its efforts on identifying prospective opportunities that provide technology-enabled solutions with high-growth, mission-critical applications in government and commercial markets. The Company is not engaged in any business operations and has not generated any revenue.

Sector

More about the company